Literature DB >> 31658365

Combining designer receptors exclusively activated by designer drugs and neuroimaging in experimental models: A powerful approach towards neurotheranostic applications.

Lore M Peeters1, Stephan Missault1, Aneta J Keliris1, Georgios A Keliris1.   

Abstract

The combination of chemogenetics targeting specific brain cell populations with in vivo imaging techniques provides scientists with a powerful new tool to study functional neural networks at the whole-brain scale. A number of recent studies indicate the potential of this approach to increase our understanding of brain function in health and disease. In this review, we discuss the employment of a specific chemogenetic tool, designer receptors exclusively activated by designer drugs, in conjunction with non-invasive neuroimaging techniques such as PET and MRI. We highlight the utility of using this multiscale approach in longitudinal studies and its ability to identify novel brain circuits relevant to behaviour that can be monitored in parallel. In addition, some identified shortcomings in this technique and more recent efforts to overcome them are also presented. Finally, we discuss the translational potential of designer receptors exclusively activated by designer drugs in neuroimaging and the promise it holds for future neurotheranostic applications.
© 2019 The British Pharmacological Society.

Mesh:

Substances:

Year:  2020        PMID: 31658365      PMCID: PMC7042113          DOI: 10.1111/bph.14885

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  62 in total

1.  Hypersynchronicity in the default mode-like network in a neurodevelopmental animal model with relevance for schizophrenia.

Authors:  Stephan Missault; Cynthia Anckaerts; Soumaya Ahmadoun; Ines Blockx; Michaël Barbier; Kenny Bielen; Disha Shah; Samir Kumar-Singh; Winnok H De Vos; Annemie Van der Linden; Stefanie Dedeurwaerdere; Marleen Verhoye
Journal:  Behav Brain Res       Date:  2019-02-23       Impact factor: 3.332

Review 2.  Combining designer receptors exclusively activated by designer drugs and neuroimaging in experimental models: A powerful approach towards neurotheranostic applications.

Authors:  Lore M Peeters; Stephan Missault; Aneta J Keliris; Georgios A Keliris
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

3.  Multimodal Imaging for DREADD-Expressing Neurons in Living Brain and Their Application to Implantation of iPSC-Derived Neural Progenitors.

Authors:  Bin Ji; Hiroyuki Kaneko; Takafumi Minamimoto; Haruhisa Inoue; Hiroki Takeuchi; Katsushi Kumata; Ming-Rong Zhang; Ichio Aoki; Chie Seki; Maiko Ono; Masaki Tokunaga; Satoshi Tsukamoto; Koji Tanabe; Ryong-Moon Shin; Takeharu Minamihisamatsu; Seiji Kito; Barry J Richmond; Tetsuya Suhara; Makoto Higuchi
Journal:  J Neurosci       Date:  2016-11-09       Impact factor: 6.167

4.  Cre-dependent DREADD (Designer Receptors Exclusively Activated by Designer Drugs) mice.

Authors:  Hu Zhu; Dipendra K Aryal; Reid H J Olsen; Daniel J Urban; Amanda Swearingen; Stacy Forbes; Bryan L Roth; Ute Hochgeschwender
Journal:  Genesis       Date:  2016-06-03       Impact factor: 2.487

Review 5.  DREADDs for Neuroscientists.

Authors:  Bryan L Roth
Journal:  Neuron       Date:  2016-02-17       Impact factor: 17.173

Review 6.  THE CONCISE GUIDE TO PHARMACOLOGY 2019/20: Ion channels.

Authors:  Stephen P H Alexander; Alistair Mathie; John A Peters; Emma L Veale; Jörg Striessnig; Eamonn Kelly; Jane F Armstrong; Elena Faccenda; Simon D Harding; Adam J Pawson; Joanna L Sharman; Christopher Southan; Jamie A Davies
Journal:  Br J Pharmacol       Date:  2019-12       Impact factor: 8.739

7.  Reverse pharmacogenetic modulation of the nucleus accumbens reduces ethanol consumption in a limited access paradigm.

Authors:  Daniela Cassataro; Daniella Bergfeldt; Cariz Malekian; Jared X Van Snellenberg; Panayotis K Thanos; Gord Fishell; Lucas Sjulson
Journal:  Neuropsychopharmacology       Date:  2013-08-01       Impact factor: 8.294

8.  Role of Ventral Subiculum in Context-Induced Relapse to Alcohol Seeking after Punishment-Imposed Abstinence.

Authors:  Nathan J Marchant; Erin J Campbell; Leslie R Whitaker; Brandon K Harvey; Konstantin Kaganovsky; Sweta Adhikary; Bruce T Hope; Robert C Heins; Thomas E Prisinzano; Eyal Vardy; Antonello Bonci; Jennifer M Bossert; Yavin Shaham
Journal:  J Neurosci       Date:  2016-03-16       Impact factor: 6.167

9.  Designer receptors show role for ventral pallidum input to ventral tegmental area in cocaine seeking.

Authors:  Stephen V Mahler; Elena M Vazey; Jacob T Beckley; Colby R Keistler; Ellen M McGlinchey; Jennifer Kaufling; Steven P Wilson; Karl Deisseroth; John J Woodward; Gary Aston-Jones
Journal:  Nat Neurosci       Date:  2014-03-02       Impact factor: 24.884

10.  Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems.

Authors:  Ken Y Chan; Min J Jang; Bryan B Yoo; Alon Greenbaum; Namita Ravi; Wei-Li Wu; Luis Sánchez-Guardado; Carlos Lois; Sarkis K Mazmanian; Benjamin E Deverman; Viviana Gradinaru
Journal:  Nat Neurosci       Date:  2017-06-26       Impact factor: 24.884

View more
  3 in total

Review 1.  Combining designer receptors exclusively activated by designer drugs and neuroimaging in experimental models: A powerful approach towards neurotheranostic applications.

Authors:  Lore M Peeters; Stephan Missault; Aneta J Keliris; Georgios A Keliris
Journal:  Br J Pharmacol       Date:  2020-02-03       Impact factor: 8.739

Review 2.  Combining magnetic resonance imaging with readout and/or perturbation of neural activity in animal models: Advantages and pitfalls.

Authors:  Lauren Kosten; Serena Alexa Emmi; Stephan Missault; Georgios A Keliris
Journal:  Front Neurosci       Date:  2022-07-15       Impact factor: 5.152

3.  Cholinergic Modulation of the Default Mode Like Network in Rats.

Authors:  Lore M Peeters; Monica van den Berg; Rukun Hinz; Gaurav Majumdar; Isabel Pintelon; Georgios A Keliris
Journal:  iScience       Date:  2020-08-12
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.